Literature DB >> 23625756

Sepsis and thrombosis.

Marcel Levi1, Marcus Schultz, Tom van der Poll.   

Abstract

Activation of coagulation frequently occurs in severe infection and sepsis and may contribute to the development of thrombosis. Coagulation abnormalities in sepsis range from a small decrease in platelet count and subclinical prolongation of global clotting times to fulminant disseminated intravascular coagulation (DIC), characterized by simultaneous widespread microvascular thrombosis and profuse bleeding from various sites. Septic patients with severe forms of DIC may present with manifest thromboembolic disease or clinically less apparent microvascular fibrin deposition, which predominantly presents as multiple organ dysfunction. Thrombophilia is associated with a prohemostatic state and consequently with an increased tendency to develop thrombosis. Hypothetically, patients with thrombophilia may suffer from more severe coagulopathy in case of severe infection or sepsis, which may result in a more serious clinical course and an unfavorable outcome. On the basis of the knowledge of the pathogenesis of thrombosis in severe inflammation and sepsis, strategies aimed at the inhibition of coagulation activation have been developed and have been found favorable in experimental and clinical studies. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23625756     DOI: 10.1055/s-0033-1343894

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  59 in total

1.  Risk Factors for Stroke in Patients With Sepsis and Bloodstream Infections.

Authors:  Iris Yuefan Shao; Mitchell S V Elkind; Amelia K Boehme
Journal:  Stroke       Date:  2019-05       Impact factor: 7.914

2.  Evaluation of holmium laser for transurethral deroofing of severe and multiloculated prostatic abscesses.

Authors:  Chan Ho Lee; Ja Yoon Ku; Young Joo Park; Jeong Zoo Lee; Dong Gil Shin
Journal:  Korean J Urol       Date:  2015-01-30

3.  NETosis, complement, and coagulation: a triangular relationship.

Authors:  Cynthia M de Bont; Wilbert C Boelens; Ger J M Pruijn
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

Review 4.  Impact of thrombosis on pulmonary endothelial injury and repair following sepsis.

Authors:  Colin E Evans; You-Yang Zhao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-27       Impact factor: 5.464

5.  Rac1 regulates bacterial toxin-induced thrombin generation.

Authors:  Yongzhi Wang; Rundk Hwaiz; Lingtao Luo; Oscar Ö Braun; Eva Norström; Henrik Thorlacius
Journal:  Inflamm Res       Date:  2016-02-12       Impact factor: 4.575

6.  Influence of the serum levels of immunoglobulins on clinical outcomes in medical intensive-care patients.

Authors:  C Geier; J Schröder; A Tamm; S Dietz; S Nuding; K Holder; Ö Khandanpour; K Werdan; H Ebelt
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-12-17       Impact factor: 0.840

Review 7.  Hemostatic abnormalities in critically ill patients.

Authors:  Marcel Levi; Suthesh Sivapalaratnam
Journal:  Intern Emerg Med       Date:  2014-12-24       Impact factor: 3.397

8.  Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis.

Authors:  Ravi Shankar Keshari; Robert Silasi; Narcis Ioan Popescu; Maulin Mukeshchandra Patel; Hala Chaaban; Cristina Lupu; K Mark Coggeshall; Tom Eirik Mollnes; Steven J DeMarco; Florea Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

Review 9.  [Is a different view on the pathophysiology of sepsis the key for novel therapeutic options?].

Authors:  N Schlegel; S Flemming; M Meir; C-T Germer
Journal:  Chirurg       Date:  2014-08       Impact factor: 0.955

10.  Platelets at the crossroads of thrombosis, inflammation and haemolysis.

Authors:  Sebastian Vogel; Swee Lay Thein
Journal:  Br J Haematol       Date:  2018-01-30       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.